A phase I study investigated the therapeutic use of samalizumab (ALXN6000) as a CD200-CD200R immune checkpoint inhibitor in chronic lymphocytic leukemia (CLL) and multiple myeloma. This evidence concerns the gene CD200R1 and B-cell chronic lymphocytic leukemia.